Market capitalization | $28.70m |
Enterprise Value | $9.93m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.20 |
P/S ratio (TTM) P/S ratio | 3.46 |
P/B ratio (TTM) P/B ratio | 1.33 |
Revenue growth (TTM) Revenue growth | 363.92% |
Revenue (TTM) Revenue | $8.30m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a Cue Biopharma, Inc. forecast:
4 Analysts have issued a Cue Biopharma, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 8.30 8.30 |
364%
364%
|
|
Gross Profit | 4.87 4.87 |
559%
559%
|
|
EBITDA | -45 -45 |
11%
11%
|
EBIT (Operating Income) EBIT | -48 -48 |
9%
9%
|
Net Profit | -47 -47 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Daniel Passeri |
Employees | 53 |
Founded | 2014 |
Website | www.cuebiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.